ODP154 Reduction of Cardiac Adipose Tissue Volume with Short-Term Empagliflozin in Patients with Type 2 Diabetes: Results from the SIMPLE Randomized Clinical Trial

BACKGROUND: Sodium-glucose transporter 2 inhibitors (SGLT2-is) appear to have rapid clinical cardiovascular benefits in type 2 diabetes. Furthermore, SGLT2-is have known effects on fat metabolism. Cardiac adipose tissue (CAT) correlates with known markers of cardiovascular risk and left ventricular...

Descripción completa

Detalles Bibliográficos
Autores principales: Brandt-Jacobsen, Niels, Jürgens, Mikkel, Hasbak, Phillip, Gæde, Peter, Rossing, Peter, Rasmussen, Jon, Andersen, Camillla Fuchs, Forman, Julie, Faber, Jens, Inzucchi, Silvio, Gustafsson, Finn, Schou, Morten, Kistorp, Caroline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Cardiovascular Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624604/
http://dx.doi.org/10.1210/jendso/bvac150.504

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624604/
http://dx.doi.org/10.1210/jendso/bvac150.504

Ejemplares similares